VIR News and Press, Vir Biotechnology Inc.

Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types PR Newswire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , March 5, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary  — The five-year cancer sur...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference : Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will ...

2026-02-26 09:00:39 ET Vir Biotechnology Inc. (NASDAQ: VIR) shares plunged 16% on Thursday after the company revealed the pricing details of its underwritten public offering. The offering, priced at $8.50 per share, represents a 15% discount compared to Wednesday's closing price of $10....

2026-02-26 02:22:08 ET More on Vir Biotechnology Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript Vir Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation ...

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,...

2026-02-24 19:08:40 ET Denver, Colorado – Markets are experiencing a cross-sector mix of breakthrough science, regulatory acceleration, global expansion, and next-generation infrastructure demand. From advanced materials to immunotherapy and AI-enabling semiconductors, several names ...

2026-02-24 14:15:03 ET Barclays analyst issues OVERWEIGHT recommendation for VIR on February 24, 2026 07:22PM ET. The previous analyst recommendation was Overweight. VIR was trading at $9.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2026-02-24 13:30:20 ET Investment Overview Vir Biotechnology, Inc. ( VIR ) stock is soaring today , up nearly 30% in early trading, reaching >$9.5 per share, which reflects a market cap valuation of $1.33bn.... Read the full article on Seeking Alpha For furthe...

DENVER, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a cross-sector mix of breakthrough science, regulatory acceleration, and multi-gigawatt AI infrastructure commitments. From advanced materials to oncology platforms and hyperscale compute, today’s developments are shaping a...

2026-02-24 08:15:06 ET Evercore ISI analyst issues OUTPERFORM recommendation for VIR on February 24, 2026 01:02PM ET. The previous analyst recommendation was Outperform. VIR was trading at $7.43 at issue of the analyst recommendation. The overall analyst consensus : BUY....